This agreement is believed by us further demonstrates the growing interest in our Cobalamin Oral Drug Delivery Technology. This technology platform provides Access with the ability to develop a number of different formulations with improved benefits for different disease applications.. Access announces contract to develop oral formulation of proprietary injectable drugs Access Pharmaceuticals, Inc. , announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable medicines. Although the conditions of the contract have not been disclosed, Access indicated that any successful formulation developed will become at the mercy of a subsequent full-licensing agreement.The adjustments demonstrate that you need to follow patients meticulously. Healthcare professionals ought to be getting cancer patients to assess pain on visual scales whenever they discover them and adjusting remedies accordingly, commented Barni. Licensed from medwireNews with permission from Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or suggest any commercial products, services, or equipment.
Abbott to withdraw Meridia medicine from the U.S.S. Market at the request of the U.S. Food and Drug Administration . The SCOUT results are in contrast to the vast body of sibutramine data for the on-label individual people, including 46 controlled medical trials and a lot more than 6 million patient years of use accumulated over 13 years during which the product has been obtainable.